Avalo Therapeutics CFO Sullivan sells $202,437 in stock

Christopher Ryan Sullivan, the Chief Financial Officer of Avalo Therapeutics Inc. (NASDAQ: AVTX), disposed of 12,394 shares of the company's common stock on September 16, 2026, generating a total revenue of $202,437. This sale was a result of exercising stock options in an amount equal to the shares being sold. The trade was carried out in accordance with a pre-established Rule 10b5-1 trading plan that was approved on May 18, 2026.

The shares were auctioned off at an average cost of $16.3335 per share, with individual sale prices fluctuating between $15.91 and $16.65. After completing the sale, Mr. Sullivan possesses 39,900 shares of Avalo Therapeutics common stock. Since this transaction, the stock price has plummeted, currently trading at $7.17, marking a decline of more than 60% for the year.

A recent AI-generated insight suggests that the stock has faced a substantial loss over the past six months, experiencing a 48% reduction in that timeframe. Earlier that same day, Mr. Sullivan exercised his options to acquire an additional 12,394 shares of common stock at a rate of $9.88 per share, amounting to $122,452. This option grant becomes fully vested over time, with 25% of the shares becoming vested on March 28, 2025, and the rest vesting on a monthly basis thereafter, provided he remains employed by the company.

Following this exercise, he now owns 83,848 derivative securities represented by stock options. Avalo Therapeutics has recently been the subject of various analyst evaluations following updates on its drug development program. Oppenheimer has reduced its price objective for Avalo Therapeutics from $35 to $16, while maintaining an Outperform rating, citing concerns arising from AbbVie's Phase 3 results for lutikizumab, a drug with a comparable mechanism of action to Avalo's abdakibart.

Guggenheim has adjusted its position on Avalo Therapeutics from a Buy rating to Neutral, voiding its prior price target, following the data from AbbVie's INTREPID study, which indicated a slight difference in efficacy compared to a placebo. H.C. Wainwright has reaffirmed its Buy rating on Avalo Therapeutics, setting a $30 price target, expressing confidence in forthcoming study results from AbbVie's ongoing trials.

Cantor Fitzgerald has also retained an Overweight rating, emphasizing the potential of IL-1 inhibition as a mechanism for a wider immunosuppressive approach. These recent deliberations highlight the varied analyst viewpoints on Avalo Therapeutics' future outlook following the introduction of new clinical findings. This account was created with the assistance of AI and subsequently reviewed by an editor. For additional details, please refer to our Terms and Conditions.